library.onepin.app/sermorelin Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Growth Hormone

Growth Hormone Synthetic GHRH(1-29) analog

Sermorelin

Sermorelin Acetate · GHRH (1-29)

Synthetic GHRH(1-29) analogGrowth hormone secretagoguePreviously FDA-approved peptide

Sermorelin is a synthetic 29-amino acid peptide corresponding to the first 29 amino acids of endogenous GHRH (the biologically active fragment). It was the first GHRH analog developed and was previously FDA-approved as Geref for diagnostic use and pediatric growth hormone deficiency. While it has been largely superseded by Tesamorelin and CJC-1295 no DAC in modern protocols, Sermorelin remains available through compounding pharmacies and is still used in GH optimization protocols, particularly paired with GHRPs.

Quick Start
Route
SubQ injection
Start low
200-300 mcg daily
Frequency
Daily, bedtime
Timing
Fasted. 2+ hours.

Bedtime dosing on empty stomach. Same fasting rules as Ipamorelin (2+ hours). Amplifies natural nighttime GH pulse.

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
200-300 mcg daily · SubQ injection · Daily, bedtime
Lowest starting point. Hold about a week to assess tolerance before stepping up.
200-300 mcg daily
Daily, bedtime
Standard
Standard Anti-Aging
200-300 mcg · SubQ · Daily
human clinical trial · Corpas et al. 1992 (J Clin Endocrinol Metab)
200-300 mcg
Daily
Reconstitution CalculatorU-100
050100u
Draw to
units
01

How it works

Sermorelin binds GHRH receptors on pituitary somatotrophs, identical mechanism to Tesamorelin and CJC-1295 no DAC. It stimulates pulsatile GH release through cAMP/PKA signaling. As the native GHRH(1-29) sequence without additional modifications, it is more susceptible to DPP-IV degradation than modified analogs, resulting in a shorter effective window.

Sermorelin binds GHRH receptors on pituitary somatotrophs, identical mechanism to Tesamorelin and CJC-1295 no DAC. It stimulates pulsatile GH release through cAMP/PKA signaling. As the native GHRH(1-29) sequence without additional modifications, it is more susceptible to DPP-IV degradation than modified analogs, resulting in a shorter effective window.

02

What to expect

Early
Days 1–7

Days 1-7: Sleep improvements.

Mid
Weeks 2–4

Weeks 2-6: Recovery and body composition changes beginning.

Later
Weeks 4–12

Weeks 6-16: Full body composition effects.

03

Evidence

HumanStrong
AnimalPresent
In-vitroPresent
1999Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency · Prakash A, Goa KL, BioDrugs ↗review
2006Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? · Walker RF, Clinical Interventions in Aging ↗review
1996Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy · Geref International Study Group, Journal of Clinical Endocrinology & Metabolism ↗peer reviewed
1997Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women · Khorram O, Laughlin GA, Yen SS, Journal of Clinical Endocrinology & Metabolism ↗peer reviewed
04

The honest take

Previously FDA-approved

Geref was FDA-approved for GH deficiency diagnosis and pediatric treatment. Withdrawn for commercial reasons, not safety.

05

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

BPC-157BPC upregulates GH receptors
TB-500Non-overlapping mechanisms
VIPComplementary in GH syringe
IpamorelinGHRH + GHRP synergy. Same dual-pathway mechanism as Tesamorelin + Ipa.

Keep separate

TesamorelinSame GHRH receptor. Redundant.
CJC-1295 with DACDAC maleimide + conflicting GH patterns.
CJC-1295 no DACBoth GHRH analogs. Choose one.
06

Side effects & safety

Commonly reported

  • Injection site reaction
  • Mild water retention
  • Flushing

Less common & notes

  • Well-characterized safety from FDA approval history.
  • Similar GH-related side effects as Tesamorelin.
07

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
0.2h
Peak · Tmax
0.15h
Elimination
1h
Activity
2-4 hours (GH pulse triggered by injection lasts longer than peptide plasma presence)

Storage. Standard BAC water 2-8C. 28 days stability.

08

Regulatory status

Previously FDA-approved as Geref (withdrawn). Available through compounding. WADA prohibited under S2.

Put it to work

Calculate, log & track

Open Sermorelin straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Sermorelin in the app →

Go deeper

The guide & community

The complete Sermorelin walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community